Answer
Imbruvica (ibrutinib) has been associated with minor bleeding (contusion, epistaxis and petechiae) and major bleeding (gastrointestinal bleeding, intracranial haemorrhage and haematuria), some fatal, both with and without thrombocytopenia.
Sources for this answer
- IMBRUVICA 140 mg film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 25Document updated
Sources checked